Benefit Sharing. 8.1 The sharing of benefits should be discussed and negotiated between the Provider and Recipient before Materials are transferred to the Recipient.
8.2 The Parties agree to Benefit Sharing as detailed in Annexure B.
Benefit Sharing. Part-time employees shall be entitled to enroll in those employee benefits provided in Articles B.11.2 and B.11.3. Benefit premiums for such employees will be shared on the following basis: 0.1 86.5% 13.5% 0.2 73.5% 26.5% 0.3 60.0% 40.0% 0.4 46.5% 53.5% 0.5 33.5% 66.5% 0.6 to 0.9 20.0% 80.0%
Benefit Sharing. The RECIPIENT shall, if applicable, share fairly and equitably the benefits arising from their utilisation of the MATERIAL, its progeny or derivatives in accordance with the CBD. A non-exhaustive list of non- monetary and monetary benefits is given at Appendix II to the Annex to the Nagoya Protocol5.
Benefit Sharing. The benefits arising from the access and use of the Genetic Resources shall be shared fairly and equitably by the User, in accordance with the principles estab- lished in the CBD. Basic benefits to be shared include:
1. The offer to the Provider to include local researchers in the research activities, if such interest exists.
2. In case of publications or oral presentation of the research results, full acknowledgement is to be given to the source of the Genetic Resource;
3. If TK associated to the Genetic Resources is involved, the research results published or presented orally will include full acknowledgement of the source of the Genetic Resources and the TK, if so required by the providers.
4. The Provider will receive a copy of all publications;
5. Research results will be communicated to involved stakeholders (e.g. communities, indigenous people) in an adequate manner and according to reasonable requirements of the Provider;
6. If applicable, share duplicate specimens wih the repository in the Provider country in accordance with good scientific practice. In addition, the User agrees to share the following ben- efits:
Benefit Sharing. SEQUOIA has entered into contracts requiring SEQUOIA to pay portions of the payments that it may receive pursuant to Sections 5.1, 5.2, 5.3 5.4 and 5.5 to certain of its collaborators as access fees and to promote conservation of biological diversity. Such payments shall be the sole responsibility of SEQUOIA.
Benefit Sharing. If the supplied material leads to any results / products worth commercialization, a separate memorandum of understanding (MoU) shall be entered between the provider and the recipient. The terms for benefit sharing may be both monetary and/or non-monetary as per Annexure 2 of ICAR Guidelines for Intellectual Property Management and Technology Transfer/Commercialization (2006) as outlineda.
Benefit Sharing. 16.1 The benefits that the Provider will receive from the Recipient in exchange for transferring the Data to the Recipient are described in Annexure D.
16.2 Apart from the benefits listed in Annexure D, all academic publications and press releases that report on the Research Study or Project must acknowledge that the Data were provided by the Provider.
16.3 If the Data are Personal Information, all academic publications and press releases that report on the Research Study or Project must:
16.3.1 ensure that no Data Subject is identified or identifiable from the publication unless the Data Subject’s express Consent has been obtained for such publication;
16.3.2 take action to prevent discrimination, stigma or harm to any community identified in the publication; and
16.3.3 acknowledge the Data Subjects (anonymously) and where relevant the Data Subjects’ community.
16.4 If the Data were generated from bio-specimens, either directly or indirectly, or are associated with bio-specimens, each Party warrants that it did not, and will not provide any reward in money or in kind to the Data Subjects, whether directly or indirectly, excluding health research ethics committee approved compensation for:
16.4.1 expenses incurred; and
16.4.2 time, inconvenience, and risk.
Benefit Sharing. 3.1 In addition to funding of the collection, voucher specimens, and training activities set forth in Sections 2.2 - 2.4, Sequoia will provide the following, which the parties acknowledge to be an equitable compensation package as benefit-sharing for the commercialization of collected Biological Material.
3.2 Sequoia shall pay directly to IPHAMETRA-CENAREST the following fixed fees:
3.2.1 A contract signing payment of US $10,000 (ten thousand US dollars) to be paid upon execution of the Agreement.
3.2.2 An annual commercialization fee due within 60 days from the end of each calendar year in which Sequoia sells Biological material obtained from Gabon or Derivatives thereof in the amount of US $10,000 (ten thousand US dollars).
3.3 Sequoia shall pay the following variable fees (a) directly to IPHAMETRA-CENAREST if the cumulative variable fees do not exceed the total amount of the annual commercialization fee under Section 3.1.2, or (b) into a funding mechanism (Gabon Biodiversity Fund) to be established by the parties, as further defined below in paragraph 3.4, if the variable fees exceed the annual commercialization fee.
3.3.1 A royalty of 3% of Sequoia’s Net Sales of Biological Material collected under the Agreement and Derivatives thereof.
3.3.2 Milestone payments upon report of the following milestones to Sequoia by its customers, in the amounts indicated in Annex l. Sequoia will be entitled to retain the balance of milestone payments received in excess of the amount set forth in this Section, if any.
3.3.3 Fifty percent (50%) of commercial royalties Sequoia may receive from its customers based on their sales of pharmaceutical products or other commercial compounds originating from Biological Material collected under this Agreement.
3.4 Sequoia shall report annually in writing to IPHAMETRA-CENAREST on the fractionation and other research and development and commercialization relating to Biological material provided under this Agreement. The report shall include: a list of all milestones achieved during the prior year using the Biological material, all actions related to the protection of intellectual property based thereon, an accounting of Net Sales, and royalties paid under the Agreement, and any commercial applications for any Products being developed. The report shall be provided within 90 days following each anniversary of the Effective Date. This obligation shall extend beyond the termination of this Agreement with respect to Biological material co...
Benefit Sharing. 8.1 The benefits arising from the access and use of the Genetic Resources or Materials shall be shared fairly and equitably by the User with the Provider, in accordance with the principles established in the CBD.
8.2 The benefits to be shared include:
(i) Inclusion of local researchers in the research activities, if such interest exists;
(ii) In the event that the Genetic Resource is used for display, full acknowledgement of the source of origin of the Genetic Resource;
(iii) In case of publications or oral presentation of the research results, full acknowledgement is to be given to the source of the Genetic Resource;
(iv) If TK associated to the Genetic Resources is involved, the research results published or presented orally will include full acknowledgement of the source of the Genetic Resources and the TK, if so required by the providers;
(v) Providing a copy of all publications to the Provide;
(vi) Sharing of research results with the Provider;
(vii) Sharing of at least one of each sample collected in museum display or other finished condition with the Provider (including the St. Xxxxxxxxxxx National Trust, the Department of Environment and the Department of Agriculture in Nevis) in accordance with good scientific practice;
(viii) Institutional capacity building: Presentation on the work of the Smithsonian National Museum of National History, the method of collection in St. Kitts and the use of specimens, establishing of programmes for scientific and technical education and training in measures for the identification, conservation and sustainable use of the genetic resource if applicable.
(ix) If the User, in the course of the research, discovers any unforeseen commercial potential of the Genetic Resource or Material, he/she is obliged to share such information with the Provider prior to any publication of such information.
8.3 Should the Genetic Resource be used for commercial use the benefits to be shared shall include (as is applicable) in addition to the benefits stated:
(i) Joint Ownership of patents and other intellectual property rights
(ii) Sharing in Royalties
(iii) Provision of applicable Training and Technology Transfer
(iv) Commercial products e.g. drugs at cost price for the National Health System
(v) Provision of licences (including sharing of licensing fees) by common consent
8.4 The Parties shall be required to negotiate and conclude agreements on the matters outlined in Articles 8.3 (i), (ii), (iii), (iv) and (v).
Benefit Sharing. 8.1 The benefits arising from the access and use of the Genetic Resources or Materials shall be shared fairly and equitably by the User with the Provider, in accordance with the principles established in the CBD. The benefits to be shared include: Inclusion of local researchers in the research activities, if such interest exists; In the event that the Genetic Resource is used for display, full acknowledgement of the source of origin of the Genetic Resource;
